HKSE:2591

Guangzhou Innogen Pharmaceutl Grp Co Ltd · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:08 UTC

Last close

n/aHKD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-259.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
-241.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.16Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Growth is the furthest below its sector's middle: 0.16 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.00x

0.88x

1.43x

2.44x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.00x
Its own average over 1 year, 131.5M.
Profit0.88x
Its own average over 4 years, -389.1M.
Free cash flow1.43x
Its own average over 4 years, -221.9M.
Debt2.44x
Its own average over 4 years, 68.3M.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 2.44 times.

Sales is 1.00 times its own 1-year average; Profit is 0.88 times its own 4-year average; Free cash flow is 1.43 times its own 4-year average; Debt is 2.44 times its own 4-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 1-year average1.00
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit against its own 4-year average0.88
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow against its own 4-year average1.43
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt against its own 4-year average2.44
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
HKD